Developing a new treatment to enhance radiation therapy and boost the immune response in lung cancer
Development of a RUVBL1/2 Inhibitor as a Radiosensitizer and Immune Stimulator for NSCLC
['FUNDING_R01'] · UT SOUTHWESTERN MEDICAL CENTER · NIH-11078323
This study is testing a new oral medication for people with non-small cell lung cancer that helps make cancer cells more vulnerable to radiation and immune therapy, aiming to improve treatment results for those who haven't had success with current options.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UT SOUTHWESTERN MEDICAL CENTER (nih funded) |
| Locations | 1 site (DALLAS, UNITED STATES) |
| Trial ID | NIH-11078323 on ClinicalTrials.gov |
What this research studies
This research focuses on improving treatment outcomes for patients with non-small cell lung cancer (NSCLC) by developing a new oral medication that inhibits specific proteins involved in DNA repair. By blocking these proteins, the treatment aims to make cancer cells more sensitive to radiation therapy and enhance the effectiveness of immune checkpoint inhibitors. The approach seeks to address the limitations of current therapies, particularly in patients who do not respond well to existing treatments. Patients may benefit from a more effective combination of radiation and immunotherapy, potentially leading to better survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are undergoing radiation therapy or immunotherapy.
Not a fit: Patients with other types of lung cancer or those who are not receiving radiation therapy or immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for lung cancer patients, increasing their chances of survival and reducing recurrence rates.
How similar studies have performed: Previous research has shown promise in using similar approaches to enhance the effectiveness of cancer treatments, indicating potential for success in this novel strategy.
Where this research is happening
DALLAS, UNITED STATES
- UT SOUTHWESTERN MEDICAL CENTER — DALLAS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KITTLER, RALF — UT SOUTHWESTERN MEDICAL CENTER
- Study coordinator: KITTLER, RALF
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Radiation Syndrome, anti-cancer, Anti-Cancer Agents, anti-cancer drug, anti-cancer immunotherapy